Generic Labeling Rule: Will Delay Spell Doom?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA aims to finalize proposed reg that would allow ANDA holders to unilaterally make safety labeling changes by July 2016, but opposition continues to swirl.
You may also be interested in...
US FDA Gets A New Lawyer: Rebecca Wood Named Chief Counsel
Former Sidley Austin partner brings a wealth of experience in drug product liability litigation and federal preemption. She replaces agency veteran Elizabeth Dickinson, who will stay on as senior deputy to the chief counsel.
US FDA Gets A New Lawyer: Rebecca Wood Named Chief Counsel
Former Sidley Austin partner brings a wealth of experience in drug product liability litigation and federal preemption. She replaces agency veteran Elizabeth Dickinson, who will stay on as senior deputy to the chief counsel.
FDA Proposes Unilateral Generic Drug Label Changes, Signaling End To Liability Shield
FDA proposed rule would allow ANDA holders to unilaterally make label changes prior to FDA’s approval; NDA and other ANDA holders would have 30 days to revise their labels once FDA approves the change.